

Australian Government

Department of Health

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry: 168180 MediHerb Adrenal Complex

ARTG entry for Medicine Listed

Sponsor Integria Healthcare Australia Pty Ltd

Postal Address PO Box 4854, EIGHT MILE PLAINS, QLD, 4113

Australia

ARTG Start Date 21/01/2010
Product Category Medicine
Status Active

Approval Area Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . MediHerb Adrenal Complex

Product Type Single Medicine Product Effective Date 22/02/2021

Permitted Indications

Traditionally used in Western herbal medicine to maintain/support adrenal gland health

Traditionally used in Western herbal medicine to maintain/support healthy adrenal gland function

Indication Requirements

Product presentation must not imply or refer to any adrenal related diseases.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

For practitioner dispensing only.

If symptoms persist consult your healthcare practitioner (or words to that effect).

Additional Product information

Container information

TypeMaterialLife TimeTemperatureClosureConditionsMultiple containersNot recordedNot recordedNot recordedNot recorded

Pack Size/Poison information

Pack Size Poison Schedule

Components

1 . Formulation 1

Dosage Form Tablet, film coated

Route of Administration Oral

Page 1 of 2



Australian Government

Department of Health

Therapeutic Goods Administration

Visual Identification

microcrystalline cellulose sodium starch glycollate

Active Ingredients		
Glycyrrhiza glabra root Extract dry concentrate standardised	250 mg	
Equivalent: Glycyrrhiza glabra (Dry)	1.75 g	
Rehmannia glutinosa rhizome Extract dry concentrate	150 mg	
Equivalent: Rehmannia glutinosa (Dry)	750 mg	
Other Ingredients (Excipients)		
calcium hydrogen phosphate dihydrate		
hypromellose		
magnesium stearate		
maltodextrin		

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.